UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 29, 2014
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 4, 2014, 6,340,863,126 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended June 29, 2014 and June 30, 2013
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 29, 2014 and June 30, 2013
Condensed Consolidated Balance Sheets as of June 29, 2014 and December 31, 2013
Condensed Consolidated Statements of Cash Flows for the six months ended June 29, 2014 and June 30, 2013
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
39
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
40
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
92
Item 4.
Controls and Procedures
92
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
94
Item 1A.
Risk Factors
94
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
95
Item 3.
Defaults Upon Senior Securities
95
Item 4.
Mine Safety Disclosures
95
Item 5.
Other Information
95
Item 6.
Exhibits
96
Signature
97
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
June 29,
2014
June 30,
2013
June 29,
2014
June 30,
2013
Revenues
12,773
12,973
24,126
25,383
Costs and expenses:
Cost of sales(a)
2,462
2,242
4,507
4,505
Selling, informational and administrative expenses(a)
3,520
3,591
6,560
6,808
Research and development expenses(a)
1,759
1,530
3,382
3,240
Amortization of intangible assets
1,001
1,140
2,118
2,359
Restructuring charges and certain acquisition-related costs
81
183
139
314
Other (income)/deductions net
(53
(1,070
570
(925
Income from continuing operations before provision for taxes on income
4,003
5,357
6,850
9,082
Provision for taxes on income
1,082
1,782
1,664
2,891
Income from continuing operations
2,921
3,575
5,186
6,191
Discontinued operations:
Income from discontinued operations net of tax
(2
141
290
Gain on disposal of discontinued operations net of tax
10,418
70
10,418
Discontinued operations net of tax
10,559
73
10,708
Net income before allocation to noncontrolling interests
2,921
14,134
5,259
16,899
Less: Net income attributable to noncontrolling interests
39
18
54
Net income attributable to Pfizer Inc.
2,912
14,095
5,241
16,845
Earnings per common share basic(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.46
0.51
0.81
0.87
Discontinued operations net of tax
1.50
0.01
1.50
Net income attributable to Pfizer Inc. common shareholders
0.46
2.00
0.82
2.37
Earnings per common share diluted(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.45
0.50
0.80
0.86
Discontinued operations net of tax
1.48
0.01
1.49
Net income attributable to Pfizer Inc. common shareholders
0.45
1.98
0.81
2.34
Weighted-average shares basic
6,368
7,042
6,379
7,115
Weighted-average shares diluted
6,444
7,117
6,460
7,185
Cash dividends paid per common share
0.26
0.24
0.52
0.48
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.
(b)
EPS amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 29,
2014
June 30,
2013
June 29,
2014
June 30,
2013
Net income before allocation to noncontrolling interests
2,921
14,134
5,259
16,899
Foreign currency translation adjustments
233
(755
158
(1,047
Reclassification adjustments(a)
171
(62
171
233
(584
96
(876
Unrealized holding gains/(losses) on derivative financial instruments
529
(57
133
Reclassification adjustments for realized (gains)/losses(b)
74
(224
86
302
75
305
29
435
Unrealized holding gains/(losses) on available-for-sale securities
(15
(178
93
(188
Reclassification adjustments for realized (gains)/losses(b)
(79
74
(178
(84
(94
(104
(85
(272
Benefit plans: actuarial gains/(losses), net
(11
22
(5
44
Reclassification adjustments related to amortization(c)
49
150
98
301
Reclassification adjustments related to settlements, net(c)
18
41
39
96
Other
(9
43
(26
140
47
256
106
581
Benefit plans: prior service credits and other
Reclassification adjustments related to amortization(c)
(18
(13
(36
(29
Reclassification adjustments related to curtailments, net(c)
15
11
(9
Other
(4
(1
(6
(3
(17
(26
(41
Other comprehensive income/(loss), before tax
258
(144
120
(173
Tax provision/(benefit) on other comprehensive income/(loss)(d)
187
(12
363
Other comprehensive income/(loss) before allocation to noncontrolling interests
253
(331
132
(536
Comprehensive income before allocation to noncontrolling interests
3,174
13,803
5,391
16,363
Less: Comprehensive income attributable to noncontrolling interests
24
18
31
30
Comprehensive income attributable to Pfizer Inc.
3,150
13,785
5,360
16,333
(a)
Reclassified into Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income.
(b)
Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
June 29,
2014
December 31,
2013
(Unaudited)
Assets
Cash and cash equivalents
3,406
2,183
Short-term investments
30,648
30,225
Accounts receivable, less allowance for doubtful accounts
10,388
9,357
Inventories
6,249
6,166
Current deferred tax assets and other current tax assets
4,869
4,624
Other current assets
2,727
3,689
Total current assets
58,287
56,244
Long-term investments
17,168
16,406
Property, plant and equipment, less accumulated depreciation
12,179
12,397
Goodwill
42,661
42,519
Identifiable intangible assets, less accumulated amortization
37,360
39,385
Noncurrent deferred tax assets and other noncurrent tax assets
1,383
1,554
Other noncurrent assets
3,574
3,596
Total assets
172,612
172,101
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt
5,561
6,027
Accounts payable
2,990
3,234
Dividends payable
1,650
1,663
Income taxes payable
760
678
Accrued compensation and related items
1,631
1,792
Other current liabilities
9,346
9,972
Total current liabilities
21,938
23,366
Long-term debt
32,267
30,462
Pension benefit obligations, net
4,483
4,635
Postretirement benefit obligations, net
2,621
2,668
Noncurrent deferred tax liabilities
26,309
25,590
Other taxes payable
3,800
3,993
Other noncurrent liabilities
4,238
4,767
Total liabilities
95,656
95,481
Commitments and Contingencies
Preferred stock
31
33
Common stock
454
453
Additional paid-in capital
78,208
77,283
Treasury stock
(70,535
(67,923
Retained earnings
71,627
69,732
Accumulated other comprehensive loss
(3,152
(3,271
Total Pfizer Inc. shareholders equity
76,633
76,307
Equity attributable to noncontrolling interests
323
313
Total equity
76,956
76,620
Total liabilities and equity
172,612
172,101
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS OF DOLLARS)
June 29,
2014
June 30,
2013
Operating Activities
Net income before allocation to noncontrolling interests
5,259
16,899
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
2,880
3,400
Asset write-offs, impairments and related charges
189
648
Gain associated with the transfer of certain product rights to an equity-method investment
(459
Gain on disposal of discontinued operations
(66
(10,539
Deferred taxes from continuing operations
853
1,254
Deferred taxes from discontinued operations
(2
(19
Share-based compensation expense
281
292
Benefit plan contributions (in excess of)/less than expense
(124
149
Other non-cash adjustments, net
(299
(101
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,949
(5,464
Net cash provided by operating activities
7,022
6,060
Investing Activities
Purchases of property, plant and equipment
(570
(511
Purchases of short-term investments
(21,081
(21,663
Proceeds from redemptions and sales of short-term investments
20,795
14,502
Net (purchases of)/proceeds from redemptions/sales of investments with original maturities of 90 days or less
1,399
(401
Purchases of long-term investments
(5,327
(5,233
Proceeds from redemptions and sales of long-term investments
2,947
3,194
Acquisitions of businesses, net of cash acquired
(15
Acquisitions of intangible assets
(56
(127
Other investing activities
288
171
Net cash used in investing activities
(1,605
(10,083
Financing Activities
Proceeds from short-term borrowings
2,334
Principal payments on short-term borrowings
(7
(2,333
Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less
(2,692
2,251
Proceeds from issuance of long-term debt(a)
4,491
6,618
Principal payments on long-term debt
(752
(2,394
Purchases of common stock
(2,520
(7,889
Cash dividends paid
(3,320
(3,436
Proceeds from exercise of stock options
583
1,175
Other financing activities
43
74
Net cash used in financing activities
(4,173
(3,600
Effect of exchange-rate changes on cash and cash equivalents
(21
(22
Net increase/(decrease) in cash and cash equivalents
1,223
(7,645
Cash and cash equivalents, beginning
2,183
10,081
Cash and cash equivalents, end
3,406
2,436
Supplemental Cash Flow Information
Non-cash transactions:
Sale of subsidiary common stock (Zoetis) for Pfizer common stock(b)
11,408
Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013(b)
2,479
Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)
992
Transfer of certain product rights to an equity-method investment (Hisun Pfizer)(c)
1,233
Cash paid during the period for:
Income taxes
1,068
1,305
Interest
996
1,103
(a)
In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2B. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Divestiture.
(b)
See Note 2B. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Divestiture.
(c)
See Note 2D. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and six months ended May 25, 2014 and May 26, 2013.
In the condensed consolidated statements of comprehensive income, we have revised the presentation of other comprehensive income/(loss) shown in prior periods for derivative financial instruments and available-for-sale securities, as certain items had been reported net. In the condensed consolidated statements of cash flows, we have revised the classification of certain items shown in prior periods, none of which had a significant impact.
During April and May 2014, Pfizer issued a number of announcements pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers (the Code) regarding its consideration of a possible offer for AstraZeneca PLC (AstraZeneca) and proposals made to the board of AstraZeneca in connection therewith. Pfizer announced on May 26, 2014 that it did not intend to make an offer for AstraZeneca. The announcement was made in accordance with Rule 2.8 of the Code. As a result of this announcement, Pfizer, together with any party acting in concert with Pfizer, is bound by the restrictions contained in Rule 2.8 of the Code.
On June 24, 2013, we completed the full disposition of our Animal Health business, Zoetis Inc. (Zoetis), and recognized a gain of approximately $10.4 billion, net of tax, in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013. The operating results of this business are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013. For additional information, see Note 2B. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Divestiture.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2013 Annual Report on Form 10-K.
B. Adoption of New Accounting Standards
We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our condensed consolidated financial statements:
A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.
A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.
C. Fair Value
Our fair value methodologies depend on the following types of inputs:
Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).
A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Note 2. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments
A. Acquisition
Nexium Over-the-Counter Rights
In August 2012, we entered into an agreement with AstraZeneca for the exclusive, global, over-the-counter (OTC) rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease. At that time, we made an upfront payment of $250 million to AstraZeneca, which was expensed. On March 28, 2014, the FDA approved Nexium 24HR (esomeprazole 20mg) for OTC use. Pfizer launched the product in the U.S. on May 27, 2014 and subsequently on July 11, 2014, we paid AstraZeneca a $200 million product launch milestone in accordance with the terms of the agreement. The milestone for this Consumer Healthcare asset acquisition has been recorded in Identifiable intangible assets, less accumulated amortization in the condensed consolidated balance sheet and will be amortized over its estimated useful life. AstraZeneca is eligible to receive future milestone payments of up to $350 million, based on product launches outside the U.S. and level of worldwide sales, as well as royalty payments, based on worldwide sales.
B. Divestiture
Animal Health Business (Zoetis)
On June 24, 2013, we completed the full disposition of Zoetis. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.
With respect to the formation and disposition of Zoetis, in the first six months of 2013:
Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.
Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.
Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis for Pfizer common stock and recognized a gain on sale of approximately $10.4 billion, net of income taxes resulting from certain legal entity reorganizations, which was recorded in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013.
The operating results of the Animal Health business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the three and six months ended June 30, 2013.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Total Discontinued Operations
The following table provides the components of Discontinued operations net of tax, virtually all of which relates to Zoetis:
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 29,
2014
June 30,
2013
June 29,
2014
June 30,
2013
Revenues
1,112
2,201
Pre-tax income from discontinued operations
(3
189
389
Provision for taxes on income(a)
(1
48
(1
99
Income from discontinued operations net of tax
(2
141
290
Pre-tax gain on disposal of discontinued operations(b)
10,539
66
10,539
Provision for taxes on income(b), (c)
121
(4
121
Gain on disposal of discontinued operations net of tax(b)
10,418
70
10,418
Discontinued operations net of tax
10,559
73
10,708
(a)
Includes deferred tax benefits of $2 million and $26 million for the three months ended June 29, 2014 and June 30, 2013, respectively, and deferred tax benefits of $2 million and $19 million for the six months ended June 29, 2014 and June 30, 2013, respectively.
(b)
For the three and six months ended June 29, 2014, represents post-close adjustments.
(c)
Reflects income taxes resulting from certain legal entity reorganizations.
The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the six months ended June 30, 2013, except that financing activities include the cash proceeds from the issuance of senior notes by Zoetis.
C. Collaborative Arrangement
Collaboration with Cellectis SA (Cellectis)
On June 18, 2014, we entered into a global strategic collaboration with Cellectis to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select cellular surface antigen targets. Cellectis received an upfront payment of $80 million in August 2014, and will receive funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per Pfizer product within the collaboration. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. Additionally, we entered into an agreement to acquire approximately 10% of the Cellectis capital through the purchase of newly issued shares at 9.25 Euro per share, for a total investment of approximately $35 million.
D. Equity-Method Investments
Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)
On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun), a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, 49% owned by Pfizer and 51% owned by Hisun, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. In the first quarter of 2013, we and Hisun contributed certain assets to Hisun Pfizer. Our contributions constituted a business, as defined by U.S. GAAP, and in the first six months of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income) deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets. As such, 49% of the gain, or $225 million, represented the portion of the gain associated with that indirect retained interest.
Investment in ViiV Healthcare Limited
On January 21, 2014, the European Commission approved Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV Healthcare Limited (ViiV), an equity method investee. This approval, in accordance with the agreement between GlaxoSmithKline plc and Pfizer, triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
and an increase in GlaxoSmithKline plc s equity interest in ViiV from 77.4% to 78.3%, effective April 1, 2014. As a result, in the first six months of 2014, we recognized a loss of approximately $28 million in Other (income)/deductions net.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
We can incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:
In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization and optimization actions, workforce reductions and the expansion of shared services, including the development of global systems.
All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.
At the end of 2013, we had substantially completed many of the initiatives launched in prior periods. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.
In 2014, we have the following initiatives underway:
Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of ten sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $450 million associated with prior acquisition activity and costs of approximately $1.5 billion associated with new non-acquisition-related cost-reduction initiatives.
New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $350 million.
Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $900 million.
The costs expected to be incurred during 2014-2016, of approximately $3.2 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.
Current-Period Key Activities
In the first six months of 2014, we incurred approximately $423 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
June 29,
2014
June 30,
2013
June 29,
2014
June 30,
2013
Restructuring charges(a):
Employee terminations
17
136
47
115
Asset impairments
13
12
19
115
Exit costs
36
40
15
Total restructuring charges
66
150
106
245
Integration costs(b)
15
33
33
69
Restructuring charges and certain acquisition-related costs
81
183
139
314
Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(c):